Development program

The lead program aims to develop a disease modifying osteoarthritis drug candidate based on our proprietary BMP technology. 

​

Together with our scientific and industry partners we have selected a lead product candidate in a long lasting formulation with excellent characteristics.

​

In the second half of 2022 further data will become available. When interested in meeting us and getting acquainted with our ground breaking technology and development program, please contact us.